# Biotalys NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biotalys

- Industry: Chemicals
- Headquarters: Ghent, Belgium
- Website: www.biotalys.com
- Total disclosed funding: $58M
- Latest round: Series C (Mar 12, 2020)
- Investors on record: 14

## About

Biotalys NV is a biotechnology company focused on developing innovative protein-based biocontrol solutions to enhance crop protection in agriculture, addressing pest and disease challenges sustainably.Founded in 2013 and headquartered in Ghent, Belgium, Biotalys NV specializes in creating biocontrol products for agriculture. Kevin Helash leads the company as CEO. Biotalys specializes in developing innovative protein-based biocontrol solutions aimed at enhancing crop protection. Its flagship product, Evoca™, targets crop pests and diseases, assisting farmers in reducing crop loss and food waste. The company serves agricultural producers in North America and Europe who seek sustainable alternatives to traditional pesticides.Biotalys operates on a B2B model, generating revenue through the sale of its biocontrol products, including Evoca™, which is positioned as a safe and effective means to protect crops. The revenue stream is expected to grow with the increasing demand for sustainable agricultural solutions in the US and the European Union. In May 2026, ASR Asset Management, VIB, Sofinnova Partners, PMV, Gimv, Agri Investment Fund, Ackermans & van Haaren and Belgium Federal Holding Company, along with other unspecified investors agreed to acquire 7875811 shares in Biotalys NV at EUR 1.53 apiece for EUR 12.05 million, in a PIPE transaction. The transaction was completed later that month.

## Funding rounds

- Series C, Mar 12, 2020, $11M — Novalis LifeSciences
- Series C, Jul 26, 2019, $28M — Sofinnova Partners, Gimv, Ackermans & van Haaren, PMV, Biovest, VIB, Agri Investment Fund, Qbic Fund, Madeli Participaties, K&E
- Series B, Feb 27, 2017, $3.4M — Sofinnova Partners, EXEO Capital
- Series B, Aug 12, 2016, $8.7M — Gimv, PMV, Biovest, VIB, Agri Investment Fund, Qbic Fund, Globachem NV
- Series A, Jan 7, 2013, $6.7M — Gimv, PMV, VIB, Qbic Fund, Biovest, SOFI, Madeli Participaties

## Investors

- Gimv (https://capitalatlas.ai/funds/gimv) — Series A, Series B, Series C
- PMV (https://capitalatlas.ai/funds/pmv) — Series A, Series B, Series C
- VIB — Series A, Series B, Series C
- Qbic Fund (https://capitalatlas.ai/funds/qbic-fund) — Series A, Series B, Series C
- Biovest — Series A, Series B, Series C
- SOFI — Series A
- Madeli Participaties — Series A, Series C
- Agri Investment Fund (https://capitalatlas.ai/funds/agri-investment-fund) — Series B, Series C
- Globachem NV — Series B
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series B, Series C
- EXEO Capital (https://capitalatlas.ai/funds/exeo-capital) — Series B
- Ackermans & van Haaren (https://capitalatlas.ai/funds/ackermans-van-haaren) — Series C
- K&E — Series C
- Novalis LifeSciences (https://capitalatlas.ai/funds/novalis-lifesciences) — Series C